Biology of Pain Young Investigator Grant (Archived)
The Canadian Institutes of Health Research
Rx&D Research Program (Rx&D)
In partnership with
AstraZeneca Canada Inc. (AZ)
The Canadian Pain Society (CPS)
CIHR Institute of Neurosciences, Mental Health and Addiction (INMHA)
CIHR Institute of Musculoskeletal Health and Arthritis (IMHA)
Request for Applications
| Important Dates | |
| Opportunity Launched: | October 2005 |
|
Content Last Updated: |
(No updates since launch) |
| December 15, 2005 | Letter of Intent (LOI) deadline – LOI must be courier stamped by this date. |
| January 15, 2006 | Letter of Intent decision. |
| February 15, 2006 | Full applications must be courier stamped by this date. |
| April 2006 | Peer review of applications |
| May 2006 | Anticipated notification of decision. |
| July 1, 2006 | Anticipated start date. |
| Summary | |
|
The goal of the program is to support research activities in the area of pain and enhance the understanding of pain pathophysiology and underlying mechanisms. Funds Available:
| |
Table of Contents
Background
Partners
Objectives and Relevant Research Areas
Eligibility
Allowable Costs
Peer Review Process and Evaluation Criteria
General CIHR Guidelines
Conditions of Funding
Communications Requirements
Monitoring, Performance Measurement and Evaluation
How to Apply
Contact Information
Description of Partners
Background
This program is a joint research initiative between the Canadian Pain Society, AstraZeneca Canada Inc., the CIHR Institute of Neurosciences, Mental Health and Addiction, the CIHR Institute of Musculoskeletal Health and Arthritis, and the CIHR/Rx&D Research Program. The goal of the program is to support research activities in the area of pain and enhance the understanding of pain pathophysiology and underlying mechanisms.
Partners
The CIHR/Rx&D Research Program is dedicated to identifying and developing collaborations with other CIHR institute(s), branch(es) or office(s), funding organizations and stakeholders to enhance the availability of funding for this strategic initiative, and to create, where appropriate, opportunities for knowledge exchange and translation related to the scope of this particular initiative. Applicants are invited to visit the Descriptions of Partners to find a list of partners and their respective mandates and/or strategic interests. This list will continue to evolve as new partners join in this initiative. The specific research foci and requirements for each partner are outlined in the section "Objectives and Relevant Research Areas."
Objectives and Relevant Research Areas
The specific objectives of this initiative are:
- to support research activities in the area of pain; and
- to enhance the understanding of pain pathophysiology and underlying mechanisms.
The Program will provide a research grant to young investigators (within seven years after completing postdoctoral training) for a meritorious research project in the biomedical area.
CIHR, CPS and AZ will provide funding for applications that are relevant to (in alignment with) the objectives and research priority areas described above.
Prior to peer review, Letters of Intent will be evaluated based on the following criteria:
- Research program and relevancy. Describe the program and justify why it is responsive to the RFA, including a brief description of:
- the individual research components that make up the project; and
- the objectives of the research project.
- Principal Applicant. Justify the leadership capacity of the individual identified as the Principal Applicant.
The review of applications for relevance to the strategic initiative will have no impact on the peer review process.
Eligibility
Eligibility criteria for all CIHR research funding programs apply. The business office of the institution of an eligible Nominated Principal Applicant generally administers CIHR funds. Please refer to the Eligibility Requirements for CIHR Grants and Awards regarding the eligibility requirements for individuals and institutions.
Allowable Costs
Applicants should review -A9">Use of Grant Funds and -A10">Eligibility of Expenses, Employment under Grants within the General Guidelines for All Research Grants for a complete listing and description of allowable costs and activities.
The full application must provide a detailed justification of all costs.
Grants should NOT be used:
- As bridging or emergency funding
- To support ongoing studies
Funds should be aimed at methodological or intellectual content innovations as opposed to personnel or training innovations (the latter being supported by CIHR elsewhere).
Funds may be used only for the direct costs of research (e.g., laboratory materials and supplies, hiring research/technical assistants and related travel). The purchase of equipment, up to a maximum of 50% of the value of the first year's budget, is permitted. Funds may not be used as salary for the grantees or for indirect costs of research (e.g., library, heat and light, office furniture, overhead, administrative charges and fees). In addition to the conditions outlined above, funds may only be used in the process of generating novel data in accordance with CCRA, Scientific Research and Experimental Development program.
Peer Review Process and Evaluation Criteria
A CIHR peer review committee will evaluate the full applications. Committee members are selected based on suggestions from many sources including the institute(s) / portfolio(s) and partner(s), following CIHR's Policy on Confidentiality, Conflict of Interest and Privacy Issues in Peer and Relevance Review (CCIP). For information on CIHR's peer review process in general, see Peer Review.
Peer review will be conducted in accordance with The CIHR Peer Review Process: Policies and Responsibilities of Grants Committee Members, including the standard evaluation criteria described under "Factors for Assessment" (section 6.2).
In addition, the following evaluation criteria specific to this Request for Applications will apply. CIHR recognizes that applications will emphasize different approaches to research and to knowledge translation, therefore reviewers and committees are expected to weight criteria such as these differently from one application to another.
The Research Proposed
- How important and/or original are the hypotheses or the questions to be addressed, and how clearly are they formulated?
- How important and original are the contributions expected from the research proposed? What is the potential for important new observations or knowledge?
- How well will the proposed experiments address the hypotheses or questions? How appropriate are the methods to be applied and the proposed analyses of data? How well will the applicant implement new methods that are to be introduced and/or explored? How well have the applicants anticipated difficulties in their approach and considered alternatives?
- How critically is the relevant literature appraised and evaluated?
The Applicant's Productivity, Experience and Training
- How appropriate to the research proposed is the training or track record of the applicant(s)? How important and original is the recent productivity of the applicant(s)? How much confidence do you have that the applicant can do the work proposed? (The proposed time commitment to the research may influence this judgment.)
Upon completion of peer review, all Partners will receive the ranking list, merit scores (ratings) and recommendations of the peer review committee with regards to funding level and award term, for the submitted applications that fall in the fundable range and have been determined to be relevant to the specific research areas and objectives of the initiative. The list will be used for funding decision-making purposes and will remain anonymous.
General CIHR Guidelines
This Request for Applications will follow the General Guidelines for All Research Funding Grants and General Guidelines for Industry-Partnered Programs.
Conditions of Funding
All conditions specified in CIHR General Grants and Awards Policies shall apply to applications funded through this Request for Applications. Conditions cover areas such as Applicant and Institutional Responsibilities, Ethics, Official language policy, Access to Information and Privacy Acts, and Acknowledgement of CIHR Support. Successful applicants will be informed of any special financial conditions prior to the release of funds or when they receive CIHR's Authorization for Funding (AFF) document.
Access to Information Act and Privacy Act, and the Personal Information Protection and Electronic Documents Act (PIPEDA)
All personal information collected by CIHR about applicants is used to review applications, to administer and monitor grants and awards, to compile statistics, and to promote and support health research in Canada. Consistent with these purposes, applicants should also expect that information collected by CIHR may be shared as described in Use and Disclosure of Personal Information Provided to CIHR for Peer Review.
CIHR as a federal entity is subject to the Access to Information Act and the Privacy Act, therefore the requirements of these two statutes will apply to all information located in CIHR's premises including, without limitation, cost-sharing agreements related to this Request for Applications and all matters pertaining thereto.
While respecting the application of the Privacy Act to federal entities, all signing parties involved in a collaborative agreement will also be bound by the Personal Information Protection and Electronic Documents Act (PIPEDA). All personal information (as identified by the PIPEDA) collected, used or disclosed in the course of any commercial activity under collaborative agreements related to the Request for Applications will be collected, used and disclosed in compliance with the PIPEDA.
Communications Requirements
Grant recipients are required to acknowledge CIHR, its institutes and partners in any communication or publication related to the project. See CIHR General Grants and Awards Policies, Acknowledgement of CIHR's Support for details on CIHR's communication requirements. The contributing institutes / partners will be identified on the Authorization for Funding and decision letter.
Monitoring, Performance Measurement and Evaluation
CIHR is committed to demonstrating results to Canadians for the money invested in health research. Therefore, processes for monitoring progress and appropriate use of funds, as well as for performance measurement and program evaluation are in place. As a result, funding recipients must:
- contribute to the monitoring, review and evaluation of CIHR's programs, policies and processes by participating in evaluation studies, surveys, workshops, audits and providing data or reports as required for the purpose of collecting information to assess progress and results;
- encourage their associates, trainees and administration to participate in the monitoring, review and evaluation of CIHR's programs, policies and processes as required.
How to Apply
The application process is comprised of two steps: 1) Letter of Intent (LOI), and 2) Full Application.
1) Letter of Intent (LOI)
The Letter of Intent is comprised of:
i) the first two pages of the CIHR Research Module for the CIHR Operating Grants Program (Research Module, Page 1, and Page 2a);
ii) a three page letter; and
iii) attachments.
i) CIHR Research Module:
The Research Module must be completed using the Webforms:
- Note: page numbers will not be identified while you are entering the data. While you must complete all of the sections of this form for the full application, for the purposes of the Letter of Intent, it is sufficient to complete only the following sections: "Research Funding Program," "Nominated Principal Applicant/Candidate," and "Project".
- Indicate Biology of Pain Young Investigators Grant in the section: "Name of Strategic Initiative (RFA)"
- Once you have completed these sections, Save and Exit, then chose the print option for "Registration Pages Only." You will then be able to choose to print only the first two pages of the form.
- On the Research Module, Page 1, signatures are required from the appropriate authorities at the Nominated Principal Applicant's employing institution.
- On the Research Module, Page 2a, only the signature of the Nominated Principal Applicant is required.
ii) Letter
The letter itself must not exceed three (3) pages and must address the following:
- Research program and relevancy. Describe the project and justify why it is responsive to this Request for Applications, including a brief description of the:
- Individual research components that make up the project;
- Objectives of the research project;
- Principal Applicant: Justify the leadership capacity of the individual identified as the Principal Applicant.
iii) Attachments
- An abbreviated CV (maximum two pages) for the Principal Applicant and each co-applicant, using the Common CV as a guideline for content. This must include information on current grants held, relevant publications from the last five years, and expertise keywords.* Full CVs will not be accepted.
- A short bibliography (one page) of any references cited in the letter of intent
- A list of the areas of expertise of the team members
Applicants are advised to follow the ">Mandatory Instructions for Data Entry which outline formatting requirements for attachments.
Submit one original and six copies of the Letter of Intent to the address below, by the deadline date indicated at the beginning of this Request for Applications.
Applicants that successfully pass the relevancy review will receive an invitation to submit a full application.
2) Full Application
Review the application instructions provided in How to Apply for Funding.
Select "Operating Grants - Industry Partnered" from the Grant Programs Application Packages.
Submit one original and eight copies of the full application to the address below, by the deadline date indicated at the beginning of this Request for Applications.
Send the Letters of Intent and Applications by Courier to:
RE: "Biology of Pain Young Investigators Grant"
Innovation and Industry Programs
Canadian Institutes of Health Research
Room 97, 160 Elgin Street
Address locator: 4809A
Ottawa, Ontario K1A 0W9
Contact Information
For questions on CIHR funding guidelines, how to apply, and the peer review process contact:
Jacqueline Jorge
Program Delivery Coordinator
Innovation and Industry Programs
Canadian Institutes of Health Research
Tel: (613) 952-5728
Fax: (613) 954-1800
E-mail: jjorge@cihr-irsc.gc.ca
Description of Partners: CIHR and Partner Organizations
Canadian Institutes of Health Research (CIHR)
CIHR is Canada's major federal funding agency for health research. Its objective is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system.
The CIHR Institute of Neurosciences, Mental Health and Addiction (INMHA) supports research to enhance mental health, neurological health, vision, hearing, and cognitive functioning and to reduce the burden of related disorders through prevention strategies, screening, diagnosis, treatment, support systems, and palliation.
The CIHR Institute of Musculoskeletal Health and Arthritis (IMHA) is committed to sustaining health and enhancing quality of life by eradicating the pain, suffering and disability caused by the broad array of musculoskeletal (MSK) diseases and conditions.
CIHR/Rx&D Research Program (CIHR/Rx&D) is a partnership between Canada's Research-Based Pharmaceutical Companies (Rx&D) and CIHR established to provide an opportunity for health researchers to work in collaboration with Rx&D companies. Research undertaken must be beneficial to both partners with a view to improving the quality of health of Canadians.
Partners:
Canadian Pain Society (CPS) is a society of scientists, health care professionals and educators with an interest in the study of pain, its mechanisms, the assessment and treatment of clinical pain, and the dissemination of knowledge about pain.
AstraZeneca Canada Inc. (AZ) is an international pharmaceutical company with a strong research base and product portfolio designed to fight disease in seven areas of medical need including the central nervous system (CNS). The company's CNS research portfolio is focused on the areas of chronic pain management and both neurologic and psychiatric disease.